Monovalent anti-huTNFR1 antibodies, encoding nucleic acids thereof and methods of treatment thereof

US10689452B2 · kind B2 · utility

Assignees

• UNIVERSITAT STUTTGART · DE
• BALIOPHARMA AG · CH

Inventors

• Roland Kontermann · Jeffery Road, DE
• Klaus Pfizenmaier · Tiefenbronn, DE
• Fabian RICHTER · Kirchheim unter Teck, DE
• Kirstin Zettlitz · West Hollywood, US
• Peter Scheurich · Stuttgart, DE
• Andreas Herrmann · Stuttgart, DE

Key dates

• Filing date: Apr 4, 2017
• Grant date: Jun 23, 2020
• Expiry date: Apr 4, 2037

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/94
• WIPO field: Biotechnology
• WIPO sector: Chemistry

Abstract

The invention provides for an inhibitor of the huTNFRI receptor which is a human or humanized antibody construct that monovalently recognizes huTNFRI through an antigen-binding moiety, which is characterized by specific CDR sequences, a pharmaceutical preparation thereof, method of producing the inhibitor and the medical use of the inhibitor.